Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571697 · ClinicalTrials.gov registry record
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 34,647
- Enrollment target
NCT04571697 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 34,647 participants.
The verdict
NCT04571697 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 34,647 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the risk of dementia in participants diagnosed with rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those exposed to methotrexate.
Interventions
- DRUG Methotrexate
- DRUG Anti-TNF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34,647 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2020-10-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04571697
The ClinicalTrials.gov registry entry for NCT04571697 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34,647 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT04571697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04571697 about?
NCT04571697 is a clinical study titled "A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy". The purpose of the study is to compare the risk of dementia in participants diagnosed with rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those exposed to methotrexate.
What is the current status of trial NCT04571697?
This trial is currently completed. The enrollment target is 34,647 participants. The study started on 2020-09-28. Estimated completion is 2020-10-27.
What interventions are being tested in trial NCT04571697?
The interventions under investigation include: Methotrexate (DRUG), Anti-TNF (DRUG).
Who is sponsoring clinical trial NCT04571697?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.